Thrombocytosis
8
1
1
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.5%
1 terminated out of 8 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Molecular Biology of Polycythemia and Thrombocytosis
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Predictors of Reactive Thrombocytosis in Critically Ill Septic Patients
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions
The Role of Reactive Thrombocytosis in Children With Pneumococcal Infection
Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)